FDA Issues Final Guidance to Expand Cancer Clinical Trial Access

The U.S. Food and Drug Administration (FDA) has finalized guidance to broaden eligibility criteria for cancer clinical trials. This initiative aims to make trials more inclusive by adjusting standards for patient performance, concomitant medications, and laboratory values. The change could expand access for a wider range of patients and potentially accelerate cancer research and development.